$33.13
2.10% today
NYSE, Nov 07, 06:16 pm CET
ISIN
US83175M2052
Symbol
SNN

Smith & Nephew PLC Sponsored ADR Stock price

$32.45
-3.46 9.64% 1M
+4.01 14.10% 6M
+7.87 32.02% YTD
+7.97 32.56% 1Y
+8.24 34.04% 3Y
-4.55 12.30% 5Y
-1.30 3.85% 10Y
+15.02 86.19% 20Y
NYSE, Closing price Thu, Nov 06 2025
-4.31 11.72%

Key metrics

Basic
Market capitalization
$15.5b
Enterprise Value
$18.3b
Net debt
$2.8b
Cash
$676.0m
Shares outstanding
876.0m
Valuation (TTM | estimate)
P/E
57.9 | 27.9
P/S
2.6 | 2.5
EV/Sales
3.1 | 2.9
EV/FCF
23.0
P/B
2.8
Dividends
DPS
$0.76
Yield 1Y | 5Y
2.4% | 2.4%
Growth 1Y | 5Y
1.6% | 0.3%
Payout 1Y | 3Y
159.6% | 218.5%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$5.9b | $6.3b
EBITDA
$1.1b | $1.7b
EBIT
$891.0m | $1.1b
Net Income
$491.0m | $1.0b
Free Cash Flow
$797.0m
Growth (TTM | estimate)
Revenue
5.4% | 7.9%
EBITDA
19.9% | 48.6%
EBIT
28.0% | 27.8%
Net Income
61.0% | 147.5%
Free Cash Flow
164.8%
Margin (TTM | estimate)
Gross
70.0%
EBITDA
17.9% | 26.6%
EBIT
15.0%
Net
8.3% | 16.3%
Free Cash Flow
13.4%
Financial Health
Equity Ratio
50.9%
Return on Equity
7.8%
ROCE
9.7%
ROIC
8.4%
Debt/Equity
0.6
More
EPS
$0.6
FCF per Share
$0.9
Short interest
0.6%
Employees
17k
Rev per Employee
$330.0k
Show more

Is Smith & Nephew PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Smith & Nephew PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

13x Buy
57%
10x Hold
43%

Analyst Opinions

23 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

Buy
57%
Hold
43%

Financial data from Smith & Nephew PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5,944 5,944
5% 5%
100%
- Direct Costs 1,781 1,781
2% 2%
30%
4,163 4,163
7% 7%
70%
- Selling and Administrative Expenses 2,803 2,803
4% 4%
47%
- Research and Development Expense 295 295
5% 5%
5%
1,065 1,065
20% 20%
18%
- Depreciation and Amortization 174 174
9% 9%
3%
EBIT (Operating Income) EBIT 891 891
28% 28%
15%
Net Profit 491 491
61% 61%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Smith & Nephew PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Smith & Nephew PLC Sponsored ADR Stock News

Neutral
Seeking Alpha
one day ago
Smith & Nephew plc ( SNN ) Q3 2025 Sales Call November 6, 2025 3:30 AM EST Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets, Research Division Veronika Dubajova - Citigroup Inc., Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Graham Doyle - UBS Investment Ban...
Negative
Proactive Investors
one day ago
Smith & Nephew PLC (LSE:SN) shares were the worst faller on the FTSE 100 on Thursday morning, down 12% after reporting lower revenues than expected Third-quarter revenue growth came in at 5.0%, below consensus expectations of 6.1%, with orthopaedics slower than forecast due to a weaker performance in US knee replacement surgeries, with sport medicine also softer than expected. UBS analysts said...
Neutral
Seeking Alpha
2 days ago
Smith & Nephew plc maintains a 'Hold' rating due to valuation concerns and limited near-term upside despite recent operational improvements. Sequential growth across all business units and a 100 basis point trading margin expansion support management's confidence in achieving full-year guidance. Technical analysis reveals significant resistance at $38 and $40-$42, with bearish intermediate sign...
More Smith & Nephew PLC Sponsored ADR News

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Deepak Nath
Employees 17,349
Founded 1856
Website www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today